Surrey Heartlands

Joint Formulary & PAD

Tolvaptan - Hyponatraemia in cancer

You are here : Home > Formulary Search > Tolvaptan - Hyponatraemia in cancer

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
R
Restrictions / Comments :

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Tolvaptan
Indication :
Hyponatraemia in cancer
Group Name :
Keywords :
Brand Names Include :
Samsca
Important Information :

NHSE specialised commissioning - RSFT only

Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Other Indications

Below are listed other indications that Tolvaptan is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Hyponatraemia in cancer.

  • No records returned.

Committee Recommendations (1)

03 Aug 22 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

This drug / device falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.

Clinicians / specialists within the Acute setting should only prescribe in line with their Trust formulary / pharmacy advice.

GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication